Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy
The investigators previously identified three novel HLA-A*2402-restricted epitope peptides,
which were derived from three cancer-testis antigens, URLC10, CDCA1, and KIF20A, as targets
for cancer vaccination against lung cancer. In this phase I trial, the investigators examine
using a combination of these three peptides the safety, immunogenicity, and antitumor effect
of vaccine treatment for HLA-A*2402-positive advanced non-small cell lung cancer patients
who failed to standard therapy.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of safety (NCI CTCAE version3): the number of adverse events of vaccination therapy.
Yataro Daigo, MD, PhD
Department of Medical Oncology, Shiga University of Medical Science
Japan: Ministry of Health, Labor and Welfare